Kiniksa(US:KNSA)2025-02-25 15:54Financial Performance - ARCALYST revenue for the fourth quarter of 2024 was $122.5 million[12, 27] - Full year 2024 ARCALYST revenue reached $417.0 million, representing approximately 79% year-over-year growth[12, 27] - The company anticipates ARCALYST revenue to be between $560 million and $580 million in 2025[12, 25] - The company's cash, cash equivalents, and short-term investments totaled approximately $244 million as of December 31, 2024[12, 27] Pipeline Development - A Phase 2/3 trial of KPL-387 for recurrent pericarditis is scheduled to begin in mid-2025, with Phase 2 data expected in the second half of 2026[10, 12] - KPL-387 is an independently developed monoclonal antibody targeting the IL-1-mediated signaling pathway[10] - Topline Phase 1 data for KPL-387 support potential monthly dosing via a single subcutaneous injection in liquid formulation[10] Strategic Focus - The company is prioritizing the development of novel therapies for cardiovascular indications[9, 14] - The current operating plan is expected to remain cash flow positive on an annual basis[12, 28]